Ascendis Pharma A/S (NASDAQ:ASND)
| 107.88 Delayed Data As of 3:59pm ET |  -0.92 / -0.85%Today’s Change | 64.33 Today|||52-Week Range 127.77 | -11.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $6.0B |
Company Description
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Contact Information
Ascendis Pharma A/S Tuborg Boulevard 12 Hellerup Capital Region 2900 |
Employees
Shareholders
| Mutual fund holders | 54.41% |
| Other institutional | 50.93% |
| Individual stakeholders | -- |
Top Executives
| Jan Møller Mikkelsen | President, CEO & Executive Director |
| Scott Thomas Smith | Chief Financial Officer & Senior Vice President |
| Kennett Sprogøe | Senior Vice President, Head-Innovation & Research |
| Birgitte Volck | SVP, Head-Clinical Development & Medical Affairs |
| Stina Singel | Senior Vice President & Head-Clinical Development |
